Anemia in diffuse large B-cell non-Hodgkin lymphoma: The role of interleukin-6, hepcidin and erythropoietin

Leukemia and Lymphoma

Volumn 55, Issue 2, 2014, Pages 270-275

  Tisi, Maria Chiara ^a   Bozzoli, Valentina ^a   Giachelia, Manuela ^a   Massini, Giuseppina ^a   Ricerca, Bianca Maria ^a   Maiolo, Elena ^a   D'Alo, Francesco ^a   Larocca, Luigi Maria ^a   Piciocchi, Alfonso ^b   Tjalsma, Harold ^c   Swinkels, Dorine W ^c   Voso, Maria Teresa ^a   Leone, Giuseppe ^a   Hohaus, Stefan ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anemia; Diffuse large B cell lymphoma; Erythropoietin; Hepcidin; IL 6

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; IRON METABOLISM; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; ANEMIA; ERYTHROPOIETIN; FEMALE; FERRITINS; HEPCIDINS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-6; LOGISTIC MODELS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; YOUNG ADULT;

EID: 84904287776     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.802314     Document Type: Article

References (34)

1. Moullet I, Salles G, Ketterer N., et al Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998;9: 1109-1115. (Pubitemid 28518150)
2. Morrow TJ, Volpe S, Gupta S, et al. Anemia of cancer in intermediate-grade non-Hodgkin's lymphoma. South Med J 2002;95:889-896. (Pubitemid 34858027)
3. Dumontet C, Mounier N, Munck I.N., et al Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. Br J Haematol 2002, 118:210-217. (Pubitemid 34779539)
4. Campbell J, Seymour JF, Matthews J, et al The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement Eur J Haematol 2006;76:473-480.
5. Chung R, Lai R, Wei P., et al Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 2007;110:1278-1282. (Pubitemid 47281426)
6. Sehn LH, Scott DW, Chhanabhai M, et al Impact of concordant and discordant bone marrow Involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011;29: 1452-1457.
7. Zucker S, Freidman S, Lysik RM Bone marrow erythropoiesis in anemia of infection, inflammation and malignancy. J Clin Invest 1974;53:1132-1138.
8. Miller CB, Jones RJ, Piantadosi S, et al Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322:1689-1692. (Pubitemid 20231525)
9. Keel SB, Abkowitz JL The microcytic red cell and the anemia of inflammation. N Engl J Med 2009;361:1904-1906.
10. Weiss G, Goodnough LT Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
11. Means RT. Hepcidin and cytokines in anaemia. Hematology 2004;9:357-362.
12. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011, 117:4425-4433.
13. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica 2006;91:727-732. (Pubitemid 44014536)
14. Camaschella C, Silvestri L. New and old players in the hepcidin pathway. Haematologica 2008;93:1441-1444.
15. Kroot JJ, Tjalsma H, Fleming R.E., et al Hepcidin in human iron disorders: diagnostic implications. Clin Chem 2011;57:1650-1669.
16. Nemeth E, Rivera S, Gabayan V., et al IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-1276. (Pubitemid 39069926)
17. Kemna E, Pickkers P, Nemeth E., et al Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005;106:1864-1866. (Pubitemid 41208606)
18. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009;1790:682-693.
19. Hohaus S, Massini G, Giachelia M., et al Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 2010;28:2538-2543.
20. Seymour JF, Talpaz M, Cabanillas F., et al R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995;13:575-582.
21. Preti HA, Cabanillas F, Talpaz M., et al Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997;127:186-194. (Pubitemid 27332536)
22. Giachelia M, Voso MT, Tisi M.C., et al Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated withoutcomefollowingrituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2012;53:411-416.
23. Cazzola M, Béguin Y. New tools for clinical evaluation of erythron function in man. Br J Haematol 1992;80:278-84.
24. Kroot JCC, Laarakkers CM, Geurts-Moespot A, et al Immunochemical and mass spectrometry-based serum hepcidin assays for a variety of iron metabolism disorders. Clin Chem 2010;56:1570-1579.
25. Winter SC, Shah KA, Campo L, et al Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. Clin Cancer Res 2005;11:7614-7620. (Pubitemid 41611601)
26. Cazzola M, Guarnone R, Cerani P., et al Red blood cell precursor mass as an independent determinant of serum erythropoiein level. Blood 1998;91:2139-2145. (Pubitemid 28185519)
27. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555-559. (Pubitemid 28391581)
28. Faquin WC, Schneider TJ, Goldberg MA Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987-1994.
29. Zucker S. The swinging pendulum of the anemia of cancer: erythropoietin trumps hepcidin. J Clin Oncol 2011;29:e42.
30. Ciccarelli BT, Patterson CJ, Hunter Z.R., et al Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:160-163.
31. Sharma S, Nemeth E, Chen Y.H., et al Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008;14:3262-3267.
32. Carella AM, de Souza CA, Luminari S, et al Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. Leuk Lymphoma 2013;54:53-57.
33. Katsume A, Miyai T, Suzuki H., et al Interleukin-6 overexpression cannot generate serious disorders In severe combined immunodeficiency mice. Clin Immunol Immunopathol 1997;82: 117-124. (Pubitemid 27072890)
34. Kawabata H, Tomosugi N, Kanda J., et al Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 2007;92:857-858. (Pubitemid 350155317)